|
KR102345943B1
(ko)
*
|
2011-04-28 |
2021-12-31 |
암젠 리서치 (뮌헨) 게엠베하 |
잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
US9486475B2
(en)
*
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
LT2961771T
(lt)
|
2013-02-26 |
2020-03-10 |
Roche Glycart Ag |
Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
|
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
US10101247B2
(en)
*
|
2013-07-19 |
2018-10-16 |
Rarecyte, Inc. |
Solution and method for adhering suspension components to a substrate
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
SI3149480T1
(sl)
|
2014-05-30 |
2019-05-31 |
Amgen Research (Munich) Gmbh |
Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
|
|
EP3177643B1
(en)
|
2014-08-04 |
2019-05-08 |
F.Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
PT3221356T
(pt)
|
2014-11-20 |
2020-10-29 |
Hoffmann La Roche |
Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
DK3310814T5
(da)
|
2015-06-16 |
2024-10-07 |
Hoffmann La Roche |
Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
EP3340995A4
(en)
*
|
2015-08-28 |
2019-04-03 |
The Trustees Of The University Of Pennsylvania |
METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE
|
|
CN106554414B
(zh)
*
|
2015-09-18 |
2019-04-23 |
上海科济制药有限公司 |
抗cd19全人抗体以及靶向cd19的免疫效应细胞
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
US10101248B1
(en)
*
|
2015-12-02 |
2018-10-16 |
Rarecyte, Inc. |
Solution and method for adhering suspension components to a substrate
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
JP6225321B1
(ja)
|
2016-08-31 |
2017-11-08 |
王子ホールディングス株式会社 |
ポリ硫酸ペントサンの製造方法
|
|
EP3677587A4
(en)
|
2016-08-31 |
2021-04-14 |
Oji Holdings Corporation |
XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME
|
|
US10882918B2
(en)
|
2016-09-30 |
2021-01-05 |
Hoffmann-La Roche Inc. |
Bispecific T cell activating antigen binding molecules
|
|
JP7784795B2
(ja)
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
JP6281659B1
(ja)
|
2017-02-28 |
2018-02-21 |
王子ホールディングス株式会社 |
ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
|
|
CA3065747C
(en)
|
2017-05-31 |
2024-10-01 |
Oji Holdings Corporation |
MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE
|
|
PL3683242T3
(pl)
|
2017-09-12 |
2025-03-03 |
Oji Holdings Corporation |
Polisiarczan pentozanu i sposób wytwarzania polisiarczanu pentozanu
|
|
KR20260026092A
(ko)
|
2017-09-19 |
2026-02-25 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
KR102533822B1
(ko)
|
2017-12-20 |
2023-05-17 |
오지 홀딩스 가부시키가이샤 |
폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
US12312416B2
(en)
|
2018-02-06 |
2025-05-27 |
Seattle Children's Hospital |
Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen binding molecules and methods of use
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
AU2019225174B2
(en)
|
2018-02-23 |
2025-11-20 |
Endocyte, Inc. |
Sequencing method for CAR T cell therapy
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020221792A1
(en)
*
|
2019-04-30 |
2020-11-05 |
Amgen Research (Munich) Gmbh |
Means and methods of treating burkitt lymphoma or leukemia
|
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
CN115210252A
(zh)
|
2020-02-04 |
2022-10-18 |
西雅图儿童医院（Dba西雅图儿童研究所） |
抗二硝基苯酚的嵌合抗原受体
|
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
JP2023517063A
(ja)
|
2020-03-10 |
2023-04-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
|
|
WO2021179047A1
(en)
*
|
2020-03-12 |
2021-09-16 |
Cullis Hill Sydney David |
Treatment for coronavirus infection and associated cytokine toxicity
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
MX2023003041A
(es)
*
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
CN112521513B
(zh)
*
|
2020-12-15 |
2021-08-24 |
青岛西凯生物技术有限公司 |
一种靶向cd19的嵌合抗原受体(car)及其应用
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
CN113637087A
(zh)
*
|
2021-07-09 |
2021-11-12 |
上海易慕峰生物科技有限公司 |
一种提高细胞免疫疗法安全性的嵌合受体和细胞
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2024206166A1
(en)
*
|
2023-03-31 |
2024-10-03 |
Memorial Sloan-Kettering Cancer Center |
Microenvironment actuated t-cells and uses thereof
|